Approved Uses and Potential New Benefits Currently, GLP-1 receptor agonists are approved for managing diabetes, obesity, and cardiovascular disease in overweight individuals
Programs prefer donors at a stable dose for four to eight weeks or more
December 16, 2025
This is consistent with glucagon receptor activation, which has known cardiovascular effects
Pooled safety data across 12 placebo-controlled clinical studies of glycemic control in adults with T2D 1 Adverse reactions reported in 2% of adults taking FARXIGA 10 mg (n=1193) vs placebo (n=1393) included female genital mycotic infections (6.9% vs 1.5%), nasopharyngitis (6.3% vs 6.2%), UTIs (4.3% vs 3.7%), back pain (4.2% vs 3.2%), increased urination (3.8% vs 1.7%), male genital mycotic infections (2.7% vs 0.3%), nausea (2.5% vs 2.4%), dyslipidemia (2.5% vs 1.5%), influenza (2.3% vs 2.3%), and discomfort with urination (2.1% vs 0.7%)